This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint
by Zacks Equity Research
Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.
Kaleido (KLDO) Reports Positive Results from COVID-19 Study
by Zacks Equity Research
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail
by Zacks Equity Research
Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk
by Zacks Equity Research
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
Vir Biotechnology, Inc. (VIR) Surges 32.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Lilly (LLY) COVID-19 Antibody Combo Cuts Death/Hospitalization
by Zacks Equity Research
Lilly's (LLY) combination of its antibody drugs, bamlanivimab and etesevimab cuts death and hospitalizations, per new data from the BLAZE-1 phase III study.
Lilly (LLY) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.
Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod
by Zacks Equity Research
CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Are Options Traders Betting on a Big Move in Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza
by Zacks Equity Research
Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.
Company News for Feb 18, 2021
by Zacks Equity Research
Companies in the news are: CRL, VIR, LODE, CLPS
Lilly (LLY) COVID-19 Antibody Combo Gets FDA's Emergency Nod
by Zacks Equity Research
FDA grants EUA to Eli Lilly's (LLY) COVID-19 antibody cocktail. FDA also authorizes shortened infusion time for bamlanivimab/etesevimab.
Lilly (LLY) Partners Vir/Glaxo for COVID-19 Combo Regimen
by Zacks Equity Research
Lilly (LLY) collaborates with Vir and Glaxo to develop its COVID-19 therapy, bamlanivimab, in combination with their COVID-19 antibody candidate.
Regeneron (REGN) COVID-19 Cocktail Effective Against New Variants
by Zacks Equity Research
Regeneron (REGN) reports research data confirming that antibody REGEN-COV is effective against the SARS-CoV-2 variants.
Biotech Stock Roundup: Updates From REGN, GILD & VIR, CVAC Teams Up With BAYRY
by Zacks Equity Research
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock?
by Zacks Equity Research
Investors need to pay close attention to in Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19
by Zacks Equity Research
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Glaxo's (GSK) RSV Vaccine for Pregnant Women Enters Phase III
by Zacks Equity Research
Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.
RedHill (RDHL) to Begin Study on Second Coronavirus Candidate
by Zacks Equity Research
The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.
RedHill (RDHL) Closes Enrollment for Phase II Coronavirus Study
by Zacks Equity Research
Redhill (RDHL) completes enrollment in the phase II study on opaganib in patients hospitalized with severe COVID-19 pneumonia.
Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reports a wider-than-expected loss, while sales beat estimates in the third quarter of 2020.